White matter disease: Optimizing rituximab therapy for neuromyelitis optica

Nature Reviews Neurology

Volumn 7, Issue 12, 2011, Pages 664-665

  Wingerchuk, Dean M ^a   Weinshenker, Brian G ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY; CD27 ANTIGEN; RITUXIMAB;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; B CELL DEPLETION; CD27+ MEMORY B CELL; DRUG MONITORING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; MEMORY CELL; MYELOOPTIC NEUROPATHY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RELAPSE; RETREATMENT; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; LEUKOENCEPHALOPATHIES; NEUROMYELITIS OPTICA;

EID: 83055194270     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.154     Document Type: Article

References (10)

1. Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J. & Weinshenker, B. G. The spectrum of neuromyelitis optica. Lancet Neurol. 6, 805-815 (2007). (Pubitemid 47238676)
2. Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106-2112 (2004).
3. Hinson, S. R. et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69, 2221-2231 (2007). (Pubitemid 350294677)
4. Cree, B. A. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270-1272 (2005).
5. Jacob, A. et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65, 1443-1448 (2008).
6. Pellkofer, H. L. et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76, 1310-1315 (2011).
7. Kim, S. H., Kim, W., Li, X. F., Jung, I. J. & Kim, H. J. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch. Neurol. http://dx.doi.org/10.1001/archneurol.2011.154.
8. Palace, J. et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 67, 1016-1017 (2010).
9. Shimizu, J. et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75, 1423-1427 (2010).
10. Hinson, S. R. et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch. Neurol. 66, 1164-1167 (2009).